Precigen, Inc.
HealthcareNASDAQ:PGEN · NASDAQ Global Select
-$0.08 today
Vol 4.53M · Avg 4.47M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-1198.6%
avg -215.5%
ROIC
-88.5%
avg -47.1%
ROA
-160.0%
avg -48.0%
Analysis
ROIC is currently the strongest return metric at -88.5% versus its period average of -47.1%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Helen Sabzevari | President, Chief Executive Officer & Director | $2.07M | — | 64 | $3.77M | 1.25% |
Donald Lehr | Chief Legal Officer & Corporate Secretary | $754,145.00 | — | 51 | $755,461.00 | 0.25% |
Phil Tennant | Chief Commercial Officer | $691,553.00 | — | 56 | $139,369.00 | 0.05% |
Rutul R. Shah | Chief Operating Officer | $676,101.00 | — | 45 | $497,751.00 | 0.17% |
Harry Thomasian Jr. | Chief Financial Officer | $655,515.00 | — | 64 | $554,535.00 | 0.18% |
Randal J. Kirk | Executive Chairman | $100,000.00 | — | 73 | $519,061.00 | 0.17% |
Amy R. Lankford | Senior Vice President & Head of Clinical Operations and Regulatory Affairs | — | — | — | — | — |
Bryan T. Butman | Senior Vice President & Head of CMC | — | — | 73 | — | — |
Douglas E. Brough | Senior Vice President & Head of Research | — | — | 71 | — | — |
Rob Russell | Vice President & Head of Human Resources | — | — | — | — | — |
Steven Harasym | Vice President & Head of Investor Relations | — | — | — | $0.00 | <0.01% |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
7
$235,938.25
Sells
36
$63.42M
Net Sentiment
$63.18M
Net selling
Most Active
KIRK RANDAL J
28 transactions
1–10 of 43
Analysis
Insiders reported 7 buys worth $235,938.25 and 36 sells worth $63.42M over the last 12 months. That adds up to net selling of $63.18M. KIRK RANDAL J was the most active insider with 28 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +131.9% | +10.6% (15yr)1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | N/A | N/A1 analysts |
Analysis
Recent growth has been strongest in Revenue at +131.9% over three years. Forward estimates point to Revenue at +10.6% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Terns Pharmaceuticals, Inc.
TERN
$4.77B
Dianthus Therapeutics, Inc.
NASDAQ:DNTH
$3.43B
Enliven Therapeutics, Inc.
NASDAQ:ELVN
$2.81B
Relay Therapeutics, Inc.
NASDAQ:RLAY
$2.59B
Immatics N.V.
NASDAQ:IMTX
$1.26B
Tourmaline Bio, Inc.
TRML
$1.23B
Amylyx Pharmaceuticals, Inc.
NASDAQ:AMLX
$1.21B
Nektar Therapeutics
NASDAQ:NKTR
$1.16B
Wave Life Sciences Ltd.
NASDAQ:WVE
$1.13B
ORIC Pharmaceuticals, Inc.
NASDAQ:ORIC
$856.09M
Who manages PGEN?
Precigen, Inc. (PGEN) lists 11 active executives. The top listed executive is Harry Thomasian Jr., Chief Financial Officer.
Are PGEN insiders buying or selling?
Recent insider activity shows net selling of $26.14M.
Explore More
Continue the stock analysis
Jump to another research area for this company.